Concepts of Preneoplasia for the Goal of Cancer Prevention

  • David L. Page
  • William Dupont
  • William H. Rodgers
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


“Preneoplasia” or “premalignancy” usually suppose that there are identifiable lesions which may progress in some fashion through stages to result in life-threatening neoplastic disease. In actuality, most lesions which we so recognise in humans have their premalignant implication as indicators of increased risk. It is appropriate to recognise at least 2 categories of premalignancy. One would be indicators or markers of increased risk, and the other would be lesions which are committed in a large percentage of cases to progress to invasion and metastasis. This presentation will review premalignancy, emphasising information from human breast cancer relevant to assessment of breast cancer risk and its relevance to prevention strategies.


Breast Cancer Breast Cancer Risk Benign Breast Disease Atypical Ductal Hyperplasia Atypical Hyperplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gallager HS: The developmental pathology of breast cancer. Cancer 1980, (46):905–907PubMedCrossRefGoogle Scholar
  2. 2.
    Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ and Hong WK: Commentary: Biomarkers as intermediate end points in chemoprevention trials. JNCI 1990, (82):555–560PubMedGoogle Scholar
  3. 3.
    Eustis SL: The sequential development of cancer: a morphological perspective. Toxicol Lett 1989, (49):267–281PubMedCrossRefGoogle Scholar
  4. 4.
    Foulds L: Neoplastic Development. London: Academic Press Inc, 1975 pp 1–729Google Scholar
  5. 5.
    Smart CR: Screening and early cancer detection. Semin Oncol 1990, (17):456–462PubMedGoogle Scholar
  6. 6.
    Byar DP and Freedman LS: The importance and nature of cancer prevention trials. Sem Oncol 1990, (17):413–424Google Scholar
  7. 7.
    Greenwald P, Cullen JW and Weed D: Introduction: Cancer prevention and control. Semin Oncol 1990, (17):383–390PubMedGoogle Scholar
  8. 8.
    Cuckle HS: Screening with discrimination. Br Med J 1990, (301):889–890CrossRefGoogle Scholar
  9. 9.
    Ewing J: Precancerous diseases and precancerous lesions, especially in the breast. Medical Record 1914, (86):951–958Google Scholar
  10. 10.
    Wellings SR, Jensen HM and Marcum RG: An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. JNCI 1975, (55):231–273PubMedGoogle Scholar
  11. 11.
    Foote FW and Stewart FW: Comparative studies of cancerous versus noncancerous breasts. Ann Surg 1945, (121):6–53;-197–222PubMedCrossRefGoogle Scholar
  12. 12.
    Dupont WD, Rogers LW, Vander Zwaag R and Page DL: The epidemiologic study of anatomic markers for increased risk of mammary cancer. Pathol Res Pract 1980, (166):471–480PubMedCrossRefGoogle Scholar
  13. 13.
    Dupont WD and Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, (312):146–151PubMedCrossRefGoogle Scholar
  14. 14.
    Page DL, Dupont WD, Rogers LW and Rados MS: Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985, (55):2698–2708PubMedCrossRefGoogle Scholar
  15. 15.
    Kodlin D, Winger EE and Morgenstern RG: Chronic mastopathy and breast cancer: a follow-up study. Cancer 1977, (39):2603–2607PubMedCrossRefGoogle Scholar
  16. 16.
    Black EM and Chabon AB: In situ carcinoma of the Breast. Pathol Annu 1969, (4):185–210Google Scholar
  17. 17.
    Carter CL, Corle DK and Micozzi MS: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiology 1988, (128):467–477Google Scholar
  18. 18.
    Dupont WD and Page DL: Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 1987, (125):769–779PubMedGoogle Scholar
  19. 19.
    Dupont WD, Page DL, Rogers LW and Pari FF: Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989, (63):948–957PubMedCrossRefGoogle Scholar
  20. 20.
    Hahm HA and Ip MM: Primary culture of normal rat mammary epithelial cells within a basement membrane matrix. I. Regulation of proliferation by hormones and growth factors. In Vitro Cell Dev Biol 1990, (26):791–802PubMedCrossRefGoogle Scholar
  21. 21.
    Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshida T, Sakamoto H, Terada M and Sugimura T: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1 int-2 and c-erbB-2/ear-1. Cancer Res 1989, (49):3104–3108PubMedGoogle Scholar
  22. 22.
    Ernster VL: The epidemiology of benign breast disease. Epidemiology Rev 1981, (3):184–205Google Scholar
  23. 23.
    Urbanski S, Jensen HM and Cooke G: The association of histological and radiological indicators of breast cancer risk. Br J Cancer 1988, (58):474–479PubMedCrossRefGoogle Scholar
  24. 24.
    Azzopardi J: Problems in Breast Pathology. Philadelphia: Saunders, 1979Google Scholar
  25. 25.
    Page DL, Anderson TJ, Rogers LW: Epithelial hyperplasia. In: Page DL, Anderson TJ (eds) Diagnostic Histopathology of the Breast Edinburgh: Churchill Livingstone, 1988 pp 120–156Google Scholar
  26. 26.
    Hutter RVP: Consensus meeting. Is “fibrocystic disease” of the breast precancerous? Arch Pathol Lab Med 1986, (110):171–173Google Scholar
  27. 27.
    Page DL and Dupont WD: Histopathologic Risk Factors for Breast Cancer in Women with Benign Breast Disease. Sem Surg One 1988, (4):213–217CrossRefGoogle Scholar
  28. 28.
    Foote FW and Stewart FW: Lobular carcinoma in situ. Am J Pathol 1941, (17):491–495PubMedGoogle Scholar
  29. 26.
    McDivitt RW, Rubin GL, Stevens JA and Wingo PA: Benign breast disease histology and the risk of breast cancer. Lab Invest 1988 (58):62AGoogle Scholar
  30. 30.
    Eusebi V, Foschini MA, Cook MG, Berrino F and Azzopardi JG: Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Sem Diag Path 1989, (6):165–173Google Scholar
  31. 31.
    Rosen PP, Braun DWJr and Kinne DE: The clinical significance of pre-invasive breast carcinomas. Cancer 1980, (46):919–925PubMedCrossRefGoogle Scholar
  32. 32.
    Betsill WL Jr, Rosen PP, Lieberman PH and Robbins GF: Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 1978, (239):1863–1867PubMedCrossRefGoogle Scholar
  33. 33.
    Page DL, Dupont WD, Rogers LW and Landenberger M: Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982, (49):751–758PubMedCrossRefGoogle Scholar
  34. 34.
    Page DL and Dupont WD: Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990 (66)):1326–1335PubMedCrossRefGoogle Scholar
  35. 35.
    Lagios MD, Margolin FR, Westdahl PR and Rose MR: Mammographically detected duct carcinoma in situ. Cancer 1989, (63):618–624PubMedCrossRefGoogle Scholar
  36. 36.
    Lagios MD: Duct carcinoma in situ: Pathology and treatment. Surg Clin N A 1990, (70):853–871Google Scholar
  37. 37.
    Bartkova J, Barnes DM, Millis RR and Gullick WJ: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990, (21):1164–1167PubMedCrossRefGoogle Scholar
  38. 38.
    Cardiff RD: Cellular and molecular aspects of neoplastic progression in the mammary gland. Eur J Cancer Clin Oncol 1988, (24):15–20PubMedCrossRefGoogle Scholar
  39. 39.
    Lundberg C, Skoog L, Cavvenee WK and Nordenskjold M: Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13. PNAS 1990 (84):2372CrossRefGoogle Scholar
  40. 40.
    Sager R: Tumor suppressor genes. Science 1989, 246:1406–1412PubMedCrossRefGoogle Scholar
  41. 41.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG and Udove J: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707–712PubMedCrossRefGoogle Scholar
  42. 42.
    Zajchowski D, Band V, Pauzie N, Tager A, Stampfer M and Sager R: Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res 1988, 48:7041–7047PubMedGoogle Scholar
  43. 43.
    Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B and Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988, 48:1238–1243PubMedGoogle Scholar
  44. 44.
    Cline MJ, Battifora H and Yokota J: Procto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol 1987, 5:999–1006PubMedGoogle Scholar
  45. 45.
    Bonilla M, Ramirez M, Cueto JL and et al: In vivo amplifcation and rearrangement of c-myc oncogene in human breast tumors. JNCI 1988, 80:665–671PubMedGoogle Scholar
  46. 46.
    Rio MC, Bellocq JP, Gairard B and et al: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene erbB2. Proc Natl Acad Sci USA 1987, (84):9243–9247PubMedCrossRefGoogle Scholar
  47. 47.
    Van de Vijver MJ, Peterse JL, Mooi WJ and et al: Neu protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988, (319):1239–1245PubMedCrossRefGoogle Scholar
  48. 48.
    Varley JM, Wainwright AM and Brummer WJ: An unusual alteration in c-myc in tissue from a primary breast carcinoma. Oncogene 1987, (2):431–438Google Scholar
  49. 49.
    Medina D: The preneoplastic state in mouse mammary tumorigenesis. Carcinogenesis 1988 (9):1113–1119PubMedCrossRefGoogle Scholar
  50. 50.
    Cardiff RD and Aguilar-Cordova E: Proto-neoplasia revisited: The molecular biology of mouse mammary 51 hyperplasia. Anticancer Res 1988, (8):925–934PubMedGoogle Scholar
  51. 51.
    Murayama H, Kikuchi M, Enjoji M, Morita N and Haraguchi Y: Changes in gastric mucosa that antedate gastric carcinoma. Cancer 1990 (66):2017–2026PubMedCrossRefGoogle Scholar
  52. 52.
    Lansdown M, Quirke P, Dixon MF, Axton ATR and Johnston D: High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut 1990, (31):977–983PubMedCrossRefGoogle Scholar
  53. 53.
    Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T and Ruiz B: Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res 1990, (50):4737–4740PubMedGoogle Scholar
  54. 54.
    Tosi P, Filipe Ml, Baak JPA, Luzi P, Santopietro R, Miracco C, Sforza V and Megha T: Morphometric definition and grading of gastric intestinal metaplasia. J Pathol 1990, (161):201–208PubMedCrossRefGoogle Scholar
  55. 55.
    Hamilton PW, Allen DC and Watt PCH: A combination of cytological and architectural morphometry in assessing regenerative hyperplasia and dysplasia in ulcerative colitis. Histopathol 1990, (16):59–68CrossRefGoogle Scholar
  56. 56.
    Contesso G and Petit JY: Les adenocarcinomes intracanalaires non infiltrants du sein. Bull Cancer, (Paris) 1979 (66):1–8Google Scholar
  57. 57.
    Cross AS, Azzopardi JG, Krausz T, van Noorden S and Polak JM: A morphological and immunocytochemical study of a distintive variant of ductal carcinoma in situ of the breast. Histopathol 1985, (9):21–37Google Scholar
  58. 58.
    Peaker M: Molecular endocrinology: a welcome extension to, but not a replacement for, endocrinology. J Endocrinol 1989, (120):361–362PubMedCrossRefGoogle Scholar
  59. 59.
    Muir CS: Epidemiology, basic science, and the prevention of cancer: Implications for the future. Cancer Res 1990, (50):6441–6448PubMedGoogle Scholar
  60. 60.
    Carter CL, Corle DK, Micozzi Marc S, Schatzkin Arthur and Taylor Phillip R: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988, (128):467–477PubMedGoogle Scholar
  61. 61.
    Tavassoli FA and Norris HJ: A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990, (65):518–529PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • David L. Page
    • 1
  • William Dupont
    • 1
  • William H. Rodgers
    • 1
  1. 1.Department of PathologySchool of Medicine, Vanderbilt UniversityNashvilleUSA

Personalised recommendations